Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain–Barré syndrome
Citation Manager Formats
Make Comment
See Comments

Abstract
Article abstract The authors report a patient with an axonal Guillain–Barré syndrome (acute motor axonal neuropathy) associated with anti-GM1 antibody after Haemophilus influenzae infection. The result of ELISA inhibition studies and cytochemical staining with cholera toxin suggest the presence of a GM1-like structure on the surface of H. influenzae isolated from the patient. A particular strain of H. influenzae may have a GM1-like structure and may elicit an axonal Guillain–Barré syndrome.
Guillain–Barré syndrome (GBS) is associated with a variety of antecedent infections. Much interest has centered on GBS following Campylobacter jejuni enteritis because it most frequently precedes GBS and is associated with the presence of anti-GM1 antibodies or acute motor axonal neuropathy (AMAN)—a pure motor axonal variant of GBS.1,2 It has been shown that lipopolysaccharide from C. jejuni isolated from GBS patients with anti-GM1 antibody expressed a GM1-like structure, which suggests that nerve damage may originate from a crossed immune reaction caused by shared epitopes, possibly ganglioside GM1, within the bacterial lipopolysaccharide and the axolemma.3
We describe a patient with AMAN associated with anti-GM1 antibodies subsequent to acute bronchitis caused by Haemophilus influenzae, and investigated whether the H. influenzae isolated from the patient had a GM1-like structure.
Case report.
A 30-year-old Japanese man developed acute weakness of the arms and legs 8 days after an episode of acute bronchitis. During the next 3 days he had increased difficulties with gait and grasping, and was admitted to Chiba University Hospital on day 5. On admission his sputum was still purulent. Neurologic examination showed no cranial nerve involvement. On the Medical Research Council Scale, muscle strength was graded 4/5 in the proximal muscles and 3/5 in the distal limb muscles. He was able to walk independently, although unsteadily. Deep tendon reflexes were absent. He denied having paresthesia, and his sensory examination was normal. His CSF on day 12 had 3 cells/mm3 with a protein content of 128 mg/dL. He improved gradually without plasma exchange or immunoglobulin treatment. Two months after neurologic onset he returned to normal activity but with mild atrophy of the small hand and foot muscles, and hyporflexia.
Nerve conduction studies and electromyography were performed using conventional procedures. On day 6 there were decreases noted in the amplitudes of compound muscle action potentials in the ulnar and tibial nerves. Distal latencies were normal or slightly prolonged, and conduction velocities were normal in all the nerves tested (table). Sensory nerve conduction study findings were entirely normal. AMAN was diagnosed on the basis of the electrophysiologic criteria of Ho et al.4 Electromyography of the first dorsal interossei, flexor carpi ulnaris, and tibialis anterior muscles showed decreased recruitment patterns on day 6, and ample denervation potentials on day 13.
Nerve conduction study results
Serum was obtained on day 8 from neurologic onset and stored at −80 °C until used. ELISA, as described by Yuki et al.,5 was used to measure the IgG and IgM antibodies to GM1 and GQ1b. Serum was considered positive if the optical density (OD) was more than 3 SDs above the mean value for 45 normal control sera. Each positive sample was diluted serially, starting at 1:100. Antibody titer was defined as the highest serum dilution at which the value was 0.1 or greater. The patient’s serum had high IgG anti-GM1 antibody (1:800) titer, but IgM anti-GM1 antibody and the IgG and IgM anti-GQ1b antibodies were negative.
IgG anti-C. jejuni antibodies, measured by ELISA as described elsewhere,6 were negative. Serology for recent cytomegalovirus or Epstein–Barr viral infection was also negative.
Methods.
ELISA inhibition study.
The binding of serum anti-GM1 antibody was investigated by measuring the inhibition of antibody activity after incubation of serum samples with various concentrations of whole bacteria as described elsewhere.7 The H. influenzae strain isolated from the patient was grown, then inactivated in 1% formaldehyde, and washed. Serum was incubated with the H. influenzae from the patient for 2 hours at 4 °C, after which the samples were centrifuged at 10,000 g for 10 minutes. The supernatant was tested using ELISA for residual anti-GM1 antibody activity. The percentage of inhibition was calculated as [OD (serum without bacteria) − OD (serum preincubated with bacteria)]/OD (serum without bacteria) × 100.
Cytochemical staining of the bacteria strain.
H. influenzae was stained as described elsewhere,8 and the smears were air dried on slides. After being blocked at 4 °C for 2 hours with phosphate-buffered saline–1% bovine serum albumin, each smear was covered with 30 μL of the fluorescent-labeled cholera toxin β-subunit (FITC-BCT, List Biological Laboratories, Campbell, CA), diluted 0.1 μg/mL, then kept for 2 hours at room temperature. After the washes were performed, the smear was mounted.
Results.
H.
influenzae was isolated from sputum and a swab of the throat of the patient. The isolate was serotyped nontypable (unencapsulated type) and biotyped III.
ELISA inhibition study.
Anti-GM1 antibody activity in the patient’s serum was inhibited in a dose-dependent manner by incubation with the H. influenzae from the patient (figure 1). Other bacteria (Salmonella typhimurium and Escherichia coli) isolated from patients with infectious illnesses but without neurologic involvement did not inhibit anti-GM1 antibody activity, but a control strain of H. influenzae isolated from a boy with sinobronchitis without GBS showed weak inhibition.
Figure 1. Inhibition of anti-GM1 antibody by incubation with various protein concentrations of bacteria. ▪ = Haemophilus influenzae from a Guillain–Barré syndrome (GBS) patient; ⧫ = H. influenzae from a sinobronchitis patient without GBS; ▴ = Escherichia coli; □ = Salmonella typhimurium.
Cytochemical staining of bacteria.
H. influenzae from the patient showed intense labeling when exposed to FITC-BCT (figure 2). Control nontypable H. influenzae from the sinobronchitis patient without GBS showed milder labeling. S. typhimurium and E. coli did not react with the cholera toxin.
Figure 2. Bacteria stained with fluorescence-labeled cholera toxin. H. influenzae is from a patient with Guillain–Barré syndrome. Fluorescence-labeled cholera toxin, original magnification ×600.
Discussion.
Our findings show that a particular strain of H. influenzae can elicit GBS. H. influenzae, a gram-negative bacillus, causes epiglottitis, tracheobronchitis, or pneumonia in adults. There are six capsular serotypes, a to f, and unencapsulated strains termed nontypable H. influenzae.
Because the isolate from the patient was classified nontypable, surface epitopes probably are present on the lipopolysaccharide of the outer membrane. Acute inflammatory demyelinating polyneuropathy, the classic demyelinating form of GBS, was reported to occur after vaccination with H. influenzae type b, but that vaccine was composed only of the capsule.9 Our ELISA inhibition study showed that the whole bacterium of H. influenzae could bind with serum anti-GM1 antibodies. Our patient’s antibody binding was specific because the other bacteria studied were not able to inhibit anti-GM1 antibody activity. Furthermore, the specific cytochemical staining with cholera toxin is evidence that this strain of H. influenzae has a Galβ1-3GalNAc epitope, which is shared by GM1 or GD1b.
These findings suggest that H. influenzae has a GM1-like structure and that GBS could occur because of a crossed immune reaction between a component of H. influenzae, possibly GM1, and the axolemma of the motor nerves, as has been speculated in C. jejuni-related GBS.3 Furthermore, a control strain of H. influenzae isolated from a patient with sinobronchitis but not GBS tended to bind to anti-GM1 antibodies in the ELISA inhibition study and on cytochemical staining. We speculate that other strains of H. influenzae may have GM1-like structures, but lesser amounts than the GBS-associated strain, or they may be concealed by the capsule. In addition, host susceptibility could be a possible factor in developing GBS.
Our patient showed the AMAN pattern on electrophysiologic examination and the IgG anti-GM1 antibodies characteristic of GBS after C. jejuni infection. Although diarrhea precedes GBS in the majority of AMAN patients, approximately 20% of the Chinese AMAN patients studied had an antecedent respiratory infection.2 In GBS subsequent to respiratory infection, most of which is caused by viruses, it is difficult to identify the responsible microorganism. This may explain the rarity of GBS associated with infection by H. influenzae, a relatively common agent of respiratory infection in adults. Cytomegalovirus, which also causes respiratory symptoms, is the second most common antecedent agent in GBS. These cases show involvement of sensory as well as motor nerves and evidence of peripheral nerve demyelination.10 We speculate that in axonal GBS subsequent to respiratory infection, more H. influenzae-associated cases may exist than are expected.
Acknowledgments
Acknowledgment
The authors thank Dr. Michiaki Koga of the Department of Neurology, Dokkyo University School of Medicine, for measuring anti-Campylobacter jejuni antibody.
- Received September 4, 1998.
- Accepted December 12, 1998.
References
- ↵
- ↵
- ↵
- ↵
Ho TW, Mishu B, Li CY, et al. Guillain–Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597–605.
- ↵
- ↵
- ↵
- ↵
Moody MD, Goldman M, Thomason BM. Staining bacterial smears with fluorescent antibody. I. General methods for Malleomyces pseudomallei. J Bacteriol 1956;72:357–361.
- ↵
- ↵
Visser LH, van der Meché FGA, Meulstee J, et al. Cytomegalovirus infection and Guillain–Barré syndrome : the clinical, electrophysiologic, and prognostic features. Neurology 1996;47:668–673.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndromeMolecular mimicry and host susceptibilityK. A. Sheikh, I. Nachamkin, T. W. Ho et al.Neurology, August 01, 1998 -
Articles
Acute motor axonal neuropathy after Mycoplasma infectionEvidence of molecular mimicryK. Susuki, M. Odaka, M. Mori et al.Neurology, March 22, 2004 -
Article
Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after campylobacter infectionT. W. Ho, S.-T. Hsieh, I. Nachamkin et al.Neurology, March 01, 1997 -
Articles
Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibodyS. Kuwabara, M. Asahina, M. Koga et al.Neurology, December 01, 1998